TCGA-BH-A0BF-01A-21R-A12P-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 44
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.680
- ALLOGRAFT_REJECTION+0.630
- IL6_JAK_STAT3_SIGNALING+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- INFLAMMATORY_RESPONSE+0.540
- COMPLEMENT+0.450
- KRAS_SIGNALING_UP+0.390
- IL2_STAT5_SIGNALING+0.340
- TNFA_SIGNALING_VIA_NFKB+0.340
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- MYC_TARGETS_V1-0.370
- ESTROGEN_RESPONSE_LATE-0.320
- FATTY_ACID_METABOLISM-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- DNA_REPAIR-0.260
- ADIPOGENESIS-0.240
- G2M_CHECKPOINT-0.240
- GLYCOLYSIS-0.240
- E2F_TARGETS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518127 | — | D | 0.897 |
| 2 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.889 |
| 3 | DRR168577 | — | — | 0.880 |
| 4 | SRR2779183 | — | — | 0.876 |
| 5 | SRR8613789 | — | A | 0.872 |
| 6 | MBCProject_1819_T2A_RNA | — | A | 0.870 |
| 7 | 897de94a-21ad-4ec5-b50b-1a84370f41a0 | — | — | 0.867 |
| 8 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.863 |
| 9 | SRR8518454 | — | D | 0.863 |
| 10 | TCGA-FD-A6TB-01A-12R-A33J-07 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.680 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |